Compare · BNTX vs TWST
BNTX vs TWST
Side-by-side comparison of BioNTech SE (BNTX) and Twist Bioscience Corporation (TWST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and TWST operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $28.65B, about 2.9x TWST ($10.04B).
- Over the past year, BNTX is up 8.8% and TWST is up 446.6% - TWST leads by 437.8 points.
- TWST has been more active in the news (33 items in the past 4 weeks vs 7 for BNTX).
- BNTX has more recent analyst coverage (25 ratings vs 15 for TWST).
- Company
- BioNTech SE
- Twist Bioscience Corporation
- Price
- $114.00+1.03%
- $151.63+7.80%
- Market cap
- $28.65B
- $10.04B
- 1M return
- +25.06%
- +75.54%
- 1Y return
- +8.83%
- +446.61%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2018
- News (4w)
- 7
- 33
- Recent ratings
- 25
- 15
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
- SEC Form 6-K filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
- BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
- SEC Form 6-K filed by BioNTech SE
- BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
- Amendment: SEC Form 20-F/A filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
- European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
Latest TWST
- Officer Cho Dennis sold $222,227 worth of shares (1,598 units at $139.07), decreasing direct ownership by 2% to 74,063 units (SEC Form 4) to satisfy withholding tax
- President and COO Finn Patrick John sold $562,661 worth of shares (4,046 units at $139.07), decreasing direct ownership by 2% to 210,802 units (SEC Form 4) (tax withholding)
- Chief Accounting Officer Werner Robert F. sold $213,255 worth of shares (1,523 units at $140.02), decreasing direct ownership by 3% to 44,637 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Laponis Adam sold $273,265 worth of shares (1,965 units at $139.07), decreasing direct ownership by 2% to 108,633 units (SEC Form 4) to satisfy tax liability
- Chief Executive Officer Leproust Emily M. sold $923,259 worth of shares (6,639 units at $139.07), decreasing direct ownership by 0.81% to 812,299 units (SEC Form 4) to satisfy tax liability
- SVP of Human Resources Green Paula sold $189,130 worth of shares (1,360 units at $139.07), decreasing direct ownership by 1% to 117,921 units (SEC Form 4) (tax withholding)
- Officer Cho Dennis sold $1,843,099 worth of shares (14,205 units at $129.75) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 75,661 units (SEC Form 4)
- President and COO Finn Patrick John exercised 23,355 shares at a strike of $67.85 and sold $9,217,607 worth of shares (78,355 units at $117.64) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 214,678 units (SEC Form 4)
- Twist Bioscience Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B7 filed by Twist Bioscience Corporation